Second Bidder Emerges for Rhythm, Lifting Shares 4.2%
RYTM sits 47% above its 52-week low of $74.5.
Summary
A second, unnamed bidder — speculated to be one of the world's largest pharma companies — has reportedly made a counteroffer for Rhythm, per a Betaville 'uncooked' alert cited by traders. Shares rose 4.2% on the report. This follows the WSJ report Wednesday that AstraZeneca offered about $124 per share, roughly $10 billion, for the biotech. A competing bid would put Rhythm in play at a higher price and raises the odds of an auction rather than a single-buyer negotiation. The source is an unconfirmed market rumor, so treat the identity and terms as unverified until a filing or confirmed report lands. AstraZeneca is the previously reported suitor; Rhythm is the primary affected company.
At the time of this announcement, RYTM was trading at $109.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.